Clinical Trials

Open Search
Disease Investigator Location Phase Trial Statussort descending Detail
Beta-Thalassemia
Gary Schiller, M.D.
 UCLA
  • Phase 1/2
 Active, Not Recruiting UCLA's Trial in Blood Diseases ( A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) )
HIV
Ronald Mitsuyasu, M.D.
 UCLA
  • Phase 1/2
 Closed UCLA's Trial in HIV/AIDS Diseases ( Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection )
Multiple Myeloma
Sarah Larson, M.D.
 UCLA
  • Phase 1
 Closed UCLA's Trial in Cancer Diseases ( Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a High Dose Melphalan Conditioning Regimen, With Administration of Interleukin-2, in Patients With Multiple Myeloma )
Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (Cryopreserved) UCLA
  • Phase 1/2
 Closed UCLA's Trial in Blood Diseases ( Efficacy and Safety of Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With Severe Combined Immunodeficiency Due to ADA Deficiency )
Traumatic Brain Injury
Daniel C. Lu, M.D., Ph.D.
 UCLA
  • Phase 2
 Closed UCLA's Trial in Neurological Diseases ( A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) )
Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency UCLA
  • Phase 1/2
 Closed UCLA's Trial in Blood Diseases ( Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID) )
Ischemic Stroke
Leonid Groysman, M.D.
 UCI
  • Phase 2
 Closed UCI's Trial in Neurological Diseases ( A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke )
Sickle Cell Disease
Mark Walters, MD
UCLA
  • Phase 1/2
 Not Yet Recruiting UCLA's Trial in Blood Diseases ( Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease )
HIV
Ronald Mitsuyasu, M.D.
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in HIV/AIDS Diseases ( A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients )
Lung Cancer
Steven M. Dubinett, M.D.
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Cancer Diseases ( A Phase I Trial of Intratumoral Administration of CCL21-gene Modified Dendritic Cell (DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC )
Sickle Cell Disease
Gary Schiller, M.D.;
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Diseases ( Clinical Research Study of Autologous Stem Cell Transplantation for Sickle Cell Disease (SCD) Using Peripheral Blood CD34+ Cells Modified With the Lenti/G-βAS3-FB Lentiviral Vector )
X-linked Chronic Granulomatous Disease (X-CGD) UCLA
  • Phase 1/2
 Recruiting UCLA's Trial in Blood Diseases ( A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease )
Sarcoma/Solid Tumors
Theodore Scott Nowicki, M.D., Ph.D.;
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Cancer Diseases ( Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies )
Solid Tumor
Bartosz Chmielowski, M.D.
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Cancer Diseases ( A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic )
Limbal Stem-cell Deficiency UCLA
  • Phase 1
 Recruiting UCLA's Trial in Eye Diseases ( Safety and Feasibility of Cultivated Autologous Limbal Stem Cells (cLSC) for Limbal Stem Cell Deficiency )
Sickle Cell Disease UCLA
  • Phase 1/2
 Recruiting UCLA's Trial in Blood Diseases ( Stem Cell Gene Therapy for Sickle Cell Disease )
Limbal Stem Cell Deficiency
Sophie Deng, MD, PhD
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Eye Diseases ( Stem Cell Therapy for Limbal Stem Cell Deficiency )
Non-small cell lung cancer
Edward B Garon, MD, MS
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Cancer Diseases ( CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer )
Sarcoma
Theodore Nowicki, MD
 UCLA
  • Phase 1
 Recruiting UCLA's Trial in Cancer Diseases ( Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT) )